Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

Citius Pharmaceuticals IncTrade
Virgin Galactic Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Virgin Galactic Holdings, Inc. trades at $3.28 (market cap $498.02M). The key difference: Virgin Galactic Holdings, Inc. is far larger — about 24.9× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRSPCE
Market Cap
$20.01M$498.02M
Sector
HealthIndustrials
52-Week High
$1.82$7.52
52-Week Low
$0.48$2.17
Enterprise Value
$16.23M$597.87M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Virgin Galactic Holdings, Inc.

Virgin Galactic (SPCE) trades at $3.275, up 1.39% on the day, with a bullish technical signal from moving averages. The company continues to report significant losses, with a net income margin of -19,781.3% and negative cash flow from operations of $240.14M in 2025. Recent quarters have seen earnings beats against low expectations. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29.41%/41.18%/29.41% among 17 analysts.

The outlook remains highly speculative, driven by progress in commercial spaceflight operations against persistent financial losses. Investment opportunity hinges on successful scaling and future revenue generation, but risks include cash burn, high debt, and intense competition in the space sector. The stock is suitable only for risk-tolerant investors betting on long-term commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Virgin Galactic Holdings, Inc.

Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.

Read more on SPCE